Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit Hebei Wanbang Folon Pharmaceutical obtained approval for the registration application of Shaoyao Gancao Tang Granules from China's National Medical Products Administration.
The drug is used for various spasm and pain conditions caused by insufficiency of yin and blood and malnourishment of the sinews and vessels that manifests as leg and feet spasms and
abdominal pain, according to a Monday filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments